Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan

Share via:


OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan.

Altman previously provided Retro Biosciences’ entire seed round of $180 million. Now, the startup is raising a $1 billion Series A that Altman is joining, the Financial Times reports.

Retro Biosciences, which says it plans to launch trials for drugs targeting diseases like Alzheimer’s, recently trained a model with OpenAI to turn regular cells into stem cells.

CEO Joe Betts-LaCroix told the FT he wants to move fast by discovering and developing a drug “in the 2020s.”

The startup joins other major billionaire-backed longevity efforts, including Altos Labs, which launched with $3 billion in 2022 backed by Jeff Bezos, and Unity Biotechnology, supported by both Bezos and Peter Thiel.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan


OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan.

Altman previously provided Retro Biosciences’ entire seed round of $180 million. Now, the startup is raising a $1 billion Series A that Altman is joining, the Financial Times reports.

Retro Biosciences, which says it plans to launch trials for drugs targeting diseases like Alzheimer’s, recently trained a model with OpenAI to turn regular cells into stem cells.

CEO Joe Betts-LaCroix told the FT he wants to move fast by discovering and developing a drug “in the 2020s.”

The startup joins other major billionaire-backed longevity efforts, including Altos Labs, which launched with $3 billion in 2022 backed by Jeff Bezos, and Unity Biotechnology, supported by both Bezos and Peter Thiel.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

Reddit banned 90+ subreddits ‘accidentally’ but some are worried

Reddit banned more than 90 subreddits yesterday, later...

Mealawe Secures USD 1 Million in Funding to Revolutionize...

Pune (Maharashtra) , February 06: Mealawe, a pioneering...

What 100% FDI Means For Insurance Startups

SUMMARY Union Budget 2025-26 throws open the Indian insurance...

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!